Your browser doesn't support javascript.
loading
Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders.
Schieber, Timothy; Li, Anthony; Lundberg, Jordan; Wiczer, Tracy; Voorhees, Timothy.
Afiliação
  • Schieber T; Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH.
  • Li A; Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH.
  • Lundberg J; Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH.
  • Wiczer T; Department of Pharmacy, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH.
  • Voorhees T; Department of Medicine-Hematology, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH.
Blood Adv ; 7(14): 3431-3434, 2023 07 25.
Article em En | MEDLINE | ID: mdl-36877766
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Doenças Hematológicas Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Doenças Hematológicas Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article